交银国际发表研报指，荣昌生物(09995.HK) 第二季产品销售强劲增长，收入按年增长47.6%，毛利率较去年同期提升7.3个百分点至84.4%，亏损录1.95亿元人民币，按年及按季均有所收窄。管理层维持全年产品销售增长30%以上的指引，目标明年实现收支平衡，预期至2027年撇除BD后可实现盈利。交银国际认为，荣昌生物核心产品海内外研发进展顺利，旗下“泰它西普”用于治疗干燥综合症的国内三期研究达...
Source Link交银国际发表研报指，荣昌生物(09995.HK) 第二季产品销售强劲增长，收入按年增长47.6%，毛利率较去年同期提升7.3个百分点至84.4%，亏损录1.95亿元人民币，按年及按季均有所收窄。管理层维持全年产品销售增长30%以上的指引，目标明年实现收支平衡，预期至2027年撇除BD后可实现盈利。交银国际认为，荣昌生物核心产品海内外研发进展顺利，旗下“泰它西普”用于治疗干燥综合症的国内三期研究达...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.